Prednisone worsens anxiety far more often than it helps it. A systematic review and meta-analysis of glucocorticoid users found that roughly 8% of patients experienced anxiety during treatment, and anxiety was the single most commonly reported psychiatric side effect in a large database analysis of prolonged corticosteroid use. The drug can also indirectly relieve anxiety when it controls an underlying inflammatory condition that was itself a source of distress, but the direct pharmacological effect on the brain tilts heavily toward increased nervousness, agitation, and in some cases full-blown anxiety disorders. The picture is more layered than a simple yes-or-no, though, because dose, duration, individual genetics, and age all shape how severely prednisone affects any given person’s mental state.
How Common Is Anxiety on Prednisone?
The numbers vary depending on how anxiety is measured and what population is studied. A 2024 meta-analysis pooling data from over 9,000 patients on synthetic glucocorticoids estimated that about 8% experienced anxiety, though the confidence interval was wide, ranging from 2% to 25%, reflecting real differences across studies and patient populations.1The Journal of Clinical Endocrinology & Metabolism. Neuropsychiatric Adverse Effects of Synthetic Glucocorticoids: A Systematic Review and Meta-Analysis A separate large-database study of prolonged oral corticosteroid users reported anxiety disorder as the most frequently encountered mental health condition, though at a lower prevalence of about 1%, likely because that analysis required a formal clinical diagnosis rather than self-reported symptoms.2PubMed Central. The Association Between Prolonged Use of Oral Corticosteroids and Mental Disorders: Do Steroids Have a Role in Developing Mental Disorders?
When researchers looked specifically at people with severe prednisone-dependent asthma, roughly one in five had clinically significant anxiety symptoms, compared to about 6% of people with severe asthma not on prednisone. Those on daily prednisone were about 2.5 times more likely to have anxiety than patients with mild-to-moderate asthma.3PubMed. Anxiety, depression and personality traits in severe, prednisone-dependent asthma That comparison is useful because it helps separate the anxiety caused by having a serious chronic disease from the anxiety layered on top by the medication itself. Even accounting for the stress of severe illness, prednisone users consistently showed more anxiety.
When Anxiety Typically Starts
Psychiatric side effects from prednisone tend to show up fast. A review of 70 case reports found that the median time to onset of a psychiatric disturbance was about 11 and a half days. Nearly 40% of cases emerged during the first week of treatment, roughly 62% within two weeks, and over 80% within six weeks.4Mayo Clinic Proceedings. Psychiatric Adverse Effects of Corticosteroids A smaller prospective study found an even more compressed timeline, with 86% of patients developing psychiatric effects within the first week. In clinical practice, this early onset catches many patients off guard. People often assume that a medication needs to build up in the system before side effects appear, but prednisone can shift your mood almost immediately.
These effects can also appear after stopping the drug, not just during treatment. Withdrawal itself can trigger or worsen anxiety, partly because the body’s own cortisol production has been suppressed and needs time to recover. So a person might feel fine during a short course and then experience anxiety or low mood during the taper or in the days after the last dose.
Why Prednisone Disrupts Brain Chemistry
Prednisone is converted to prednisolone in the liver, and prednisolone acts as a powerful synthetic glucocorticoid. Your brain has glucocorticoid receptors in regions that regulate emotion, memory, and stress responses, particularly the hippocampus, the amygdala, and the prefrontal cortex. When you flood those receptors with a dose of synthetic hormone that far exceeds what your body normally produces, several things happen at once.
One of the most important changes involves the balance between excitatory and inhibitory signaling. Lab studies show that synthetic glucocorticoids boost the release of glutamate, the brain’s main excitatory chemical messenger, in the hippocampus without equally boosting GABA, the main calming chemical.5PubMed Central. Non-genomic Actions of Methylprednisolone Differentially Influence GABA and Glutamate Release From Isolated Nerve Terminals of the Rat Hippocampus In hypothalamic neurons, glucocorticoids simultaneously suppress glutamate release and facilitate GABA release through entirely different signaling pathways, which shows how complicated and region-specific these effects are.6PubMed Central. Glucocorticoids regulate glutamate and GABA synapse-specific retrograde transmission via divergent nongenomic signaling pathways The net result across the brain is a tilt toward neural excitability in emotion-regulating areas, which maps directly onto the subjective experience of feeling wired, restless, or anxious.
Prednisone also disrupts the body’s stress-hormone feedback loop. Normally, your brain senses cortisol levels and adjusts production accordingly. A large dose of synthetic glucocorticoid suppresses the signaling chain from the hypothalamus to the pituitary to the adrenal glands, eventually reducing your own cortisol output.7PubMed Central. Impact of glucocorticoid therapy on hypothalamic-pituitary-adrenal axis function in pediatric nephrotic syndrome: A narrative review This suppression can leave you with a blunted ability to mount a normal stress response, which paradoxically increases vulnerability to anxiety because the system’s natural buffering capacity is compromised.8PubMed Central. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia Animal research has confirmed that prednisone treatment creates significant imbalances between excitation and inhibition in both the frontal cortex and hypothalamus.9PubMed. Analysis of brain metabolites by gas chromatography-mass spectrometry reveals the risk-benefit concerns of prednisone in MRL/lpr lupus mice
Structural Brain Changes with Long-Term Use
Beyond chemistry, prolonged corticosteroid therapy can physically change the brain. An imaging study found that patients on chronic corticosteroid treatment had significantly smaller amygdala volumes compared to control subjects. The amygdala is a brain structure central to processing fear and anxiety, and its volume correlated with how long the patient had been on corticosteroids.10PubMed Central. Amygdala Volume in Patients Receiving Chronic Corticosteroid Therapy Additional imaging work has detected changes in the temporal lobe using structural, functional, and spectroscopic methods.11PubMed. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy
These findings matter because they suggest that long-term prednisone use doesn’t just cause temporary chemical fluctuations. For people on years of maintenance therapy, there may be actual changes to brain architecture in regions that regulate emotional responses. The extent to which these changes reverse after stopping the medication is still an open question, but the majority of patients do see improvement in psychiatric symptoms once the drug is tapered or discontinued.
Dose Is the Strongest Predictor
Virtually every study on corticosteroid-related psychiatric effects points to the same conclusion: higher doses mean more problems. Psychiatric symptoms appear to be dose-related, with most disturbances emerging at higher therapeutic doses and most improvement coming when the dose is lowered.12Annals of Allergy, Asthma & Immunology. The psychiatric side effects of corticosteroids Risks vary with age, gender, dosage, and prior psychiatric history, though predicting exactly who will be affected remains difficult.13PubMed. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects
There is no universally “safe” dose. Low-dose prednisone (under 10 mg per day) carries less psychiatric risk, but it is not zero risk. And for people on pulse therapy or high-dose bursts for conditions like lupus flares, multiple sclerosis relapses, or organ transplant rejection, the likelihood of some psychiatric disturbance is substantially higher. The evidence is consistent that the majority of patients experience at least mild mood or cognitive changes during treatment, even if they do not develop a diagnosable disorder.
Can Prednisone Indirectly Reduce Anxiety?
This is where the picture gets more nuanced. If you have a condition like severe asthma, inflammatory bowel disease, or rheumatoid arthritis, the disease itself can be a major source of anxiety. Struggling to breathe, dealing with unpredictable flares, or living with severe joint pain all create psychological distress. When prednisone rapidly controls these symptoms, the relief from the underlying illness can reduce your overall anxiety even though the drug itself has anxiety-promoting effects on the brain.
Some patients describe this as a confusing paradox: they feel physically better and less anxious about their disease, but simultaneously feel jittery, on edge, or unable to sleep because of the medication. Whether the net effect on anxiety is positive or negative depends on how severe your underlying condition was, how high the prednisone dose is, and your individual neurobiology. For a person with life-threatening inflammation, a short course of prednisone that brings the disease under control may genuinely reduce total anxiety burden despite the drug’s direct psychiatric effects. For someone on a moderate dose for a less severe condition, the anxiety caused by the medication can easily outweigh any indirect benefit.
Children and Adolescents Face Similar Risks
Prednisone-related behavioral changes are well documented in children, and in some ways the effects are even more striking because children have fewer coping mechanisms. A study of children with nephrotic syndrome found that behavioral changes occurred almost exclusively at prednisone doses of 1 mg/kg every 48 hours or above. Five of eight children who were behaviorally normal at baseline developed scores in the range usually considered appropriate for referral to a mental health provider. Prednisone dose was a strong predictor of abnormal behavior, particularly aggression.14PubMed. Behavioral effects of corticosteroids in steroid-sensitive nephrotic syndrome
A larger prospective study of children with new-onset nephrotic syndrome found that after six weeks of corticosteroid therapy, roughly 60% to 73% showed borderline or clinically abnormal externalizing behavior, including aggression and attention problems. In school-age children, about 40% also showed abnormal internalizing behavior, with elevated scores specifically in the anxious/depressed domain. Most of these changes persisted at 12 weeks of observation.15PubMed. Behavioural abnormalities in children with new-onset nephrotic syndrome receiving corticosteroid therapy: results of a prospective longitudinal study Parents are often unprepared for these personality shifts and may not connect them to the medication, especially when the child’s physical health is improving.
When researchers compared dexamethasone to prednisone in children with leukemia, dexamethasone was associated with a 6% rate of behavioral toxicity including three cases of psychosis, while prednisone had a 1% rate with no psychosis cases.16Mayo Clinic Proceedings. Psychiatric Adverse Effects of Corticosteroids in Children and Adolescents However, a systematic review comparing the two drugs more broadly found no clinically meaningful differences in cognition, mood, or behavior across randomized trials.17PubMed. Does dexamethasone induce more neuropsychological side effects than prednisone in pediatric acute lymphoblastic leukemia? A systematic review The discrepancy likely reflects differences in dosing equivalencies and study designs, but the practical takeaway is that both glucocorticoids carry meaningful psychiatric risk in children.
What To Do When Prednisone Is Causing Anxiety
If you are on prednisone and experiencing new or worsened anxiety, the most important step is telling your prescribing doctor. Many patients hesitate because they assume psychiatric side effects are not “real” medical problems or because the drug is controlling a serious physical condition they are afraid to lose. But your doctor needs to know, because management options exist.
Dose reduction is usually the first approach. Because symptoms are dose-related, lowering the dose or accelerating a taper often brings improvement. When the condition being treated does not allow a dose reduction, additional medications can help. In cases of severe psychiatric disturbance like psychosis, antipsychotic medications have been used successfully. A review of patient cases found that all 13 patients treated for steroid-induced psychosis returned to their psychological baseline after the corticosteroid was discontinued or reduced in combination with pharmacological intervention, though the time to resolution varied.18PubMed Central. Pharmacological Management of Steroid-Induced Psychosis: A Review of Patient Cases
For milder anxiety that does not rise to the level of psychosis, practical strategies can help take the edge off while you ride out the course. Sleep hygiene matters more than usual because prednisone commonly disrupts sleep, and sleep loss amplifies anxiety. One small study of rheumatoid arthritis patients found that bedtime dosing of prednisolone caused sleep disturbance in a few patients, suggesting that morning dosing may be preferable for people sensitive to insomnia.19PubMed Central. Bedtime Single-Dose Prednisolone in Clinically Stable Rheumatoid Arthritis Patients Limiting caffeine, maintaining regular physical activity, and practicing structured relaxation techniques are all sensible additions during a prednisone course, though none of these have been studied specifically in the context of corticosteroid-induced anxiety.
Genetic Factors That Raise Your Risk
Researchers have started identifying genetic variations that may explain why some people develop severe psychiatric effects on corticosteroids while others tolerate them without difficulty. One gene of particular interest is FKBP5, which helps regulate how sensitive your stress-response system is to glucocorticoids. Specific variants of this gene have been linked to increased vulnerability to anxiety and depression following prolonged stress exposure.20PubMed. FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study In a separate study, certain FKBP5 alleles were found more frequently in people with major depression who also had comorbid anxiety disorders, and even among healthy controls, those same alleles were associated with personality traits linked to higher anxiety vulnerability.21PubMed. Role of allelic variants of FK506-binding protein 51 (FKBP5) gene in the development of anxiety disorders
Genetic testing for FKBP5 variants before prescribing prednisone is not standard clinical practice and probably won’t be anytime soon. But this research does help explain a frustrating experience many patients have: feeling dismissed when they report psychiatric side effects because “most people do fine on this medication.” The reality is that susceptibility is partly biological and partly unpredictable with current tools. If you have a personal or family history of anxiety disorders, depression, or other psychiatric conditions, you and your doctor should weigh that into the decision about whether prednisone is the right anti-inflammatory choice and what monitoring plan makes sense during treatment.
When Symptoms Linger After Stopping
Most prednisone-related psychiatric effects improve once the drug is discontinued, but “most” is not “all,” and “improve” is not always “disappear.” Some patients report persistent mood changes, cognitive difficulty, and heightened stress sensitivity that lasts weeks or months after their final dose. A clinical case description detailed a patient who experienced cycles of manic-like behavior and depression during high-dose prednisone treatment, followed by long-term cognitive disorganization and personality changes that persisted well beyond the treatment period.13PubMed. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects This appears to be an extreme end of the spectrum rather than the norm, but it highlights that corticosteroid effects on the brain are not always neatly reversible.
Part of the lingering problem may relate to how long the stress-hormone feedback loop takes to recover. After weeks or months of suppression, the adrenal glands need time to resume normal cortisol production. During that recovery window, your body’s ability to respond to stress is compromised, which can manifest as anxiety, fatigue, and emotional fragility. This is one reason why gradual tapering is important rather than abruptly stopping the medication, and why patients sometimes feel worse during a taper before they eventually feel better.